10-Q: BioVie Inc. Reports Q3 2025 Financial Results, Highlights Clinical Program Advancements

BioVie Inc. announces its financial results for the quarter ended March 31, 2025, and provides updates on its clinical development programs for neurodegenerative and liver diseases.

Summary

• BioVie Inc. is a clinical-stage company focused on developing therapies for chronic debilitating conditions.
• The company's lead drug candidate, bezisterim (NE3107), is being investigated for Alzheimer's disease (AD), Parkinson's disease (PD), and long COVID.
• BIV201 (continuous infusion terlipressin) is being evaluated for the treatment of ascites and other complications of advanced liver cirrhosis.
• The company reported a net loss of $2.8 million for the three months ended March 31, 2025, compared to a net loss of $8.1 million for the same period in 2024.
• Research and development expenses decreased to $1.3 million from $5.7 million year-over-year, primarily due to the completion of clinical trials in the prior fiscal year.
• Selling, general, and administrative expenses decreased to $1.6 million from $2.0 million year-over-year.
• For the nine months ended March 31, 2025, the net loss was $14.1 million, compared to $27.2 million for the same period in 2024.
• As of March 31, 2025, BioVie had working capital of $21.2 million and cash and cash equivalents of $23.2 million.
• The company's future operations are dependent on securing additional financing.
• There is substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has reduced its losses and secured a significant grant, the going concern warning and shareholder lawsuits raise serious concerns. The overall sentiment is cautiously negative.

Positives

• The net loss decreased significantly for both the three and nine months ended March 31, 2025, compared to the same periods in 2024.
• Research and development expenses decreased due to the completion of clinical trials, indicating a potential shift towards later-stage development.
• The company secured a $13.1 million clinical trial award from the U.S. Department of Defense for the long COVID program.
• The FDA authorized the Investigational New Drug (IND) application for bezisterim (NE3107) for the treatment of long COVID.
• The company is progressing with a Phase 2 study of bezisterim (NE3107) for Parkinson's disease.
• The company is finalizing the protocol design for a Phase 3 study of BIV201 for liver disease.

Negatives

• The company is in the pre-revenue stage and expects no revenues in the foreseeable future.
• The company has an accumulated deficit of $348.7 million as of March 31, 2025.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company is facing shareholder class action and derivative lawsuits related to alleged misrepresentations regarding the NM101 Phase 3 study.
• The company is dependent on securing additional financing to continue operations.

Risks

• The company's future operations are dependent on the success of its ongoing development and commercialization efforts.
• The company's ability to obtain regulatory approval for its product candidates is uncertain.
• The company faces competition from other companies developing therapies for the same indications.
• The company's ability to raise additional capital is not assured.
• The company is subject to the risks associated with clinical trials, including the possibility of adverse events or unexpected results.
• The company is facing shareholder class action and derivative lawsuits, which could result in significant costs and liabilities.
• The company's reliance on third parties to conduct clinical trials poses risks to the integrity and compliance of those trials.

Future Outlook

The company's future operations are dependent on the success of its ongoing development and commercialization efforts, as well as its ability to secure additional financing. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. There is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations.

Industry Context

BioVie operates in the competitive biotechnology and pharmaceutical industry, focusing on neurodegenerative and liver diseases. The company's efforts to develop novel therapies align with the growing need for effective treatments for these conditions, which represent significant unmet medical needs. The company's focus on inflammation and insulin resistance as key drivers of these diseases reflects an evolving understanding of disease mechanisms in the industry.

Comparison to Industry Standards

• BioVie's financial situation, with significant accumulated deficits and reliance on future financing, is not uncommon for clinical-stage biotechnology companies.
• Companies like Cassava Sciences and Anavex Life Sciences are also focused on Alzheimer's disease and face similar challenges in clinical development and regulatory approval.
• The $13.1 million grant from the Department of Defense is a positive sign, but the company's overall financial stability remains a concern.
• The company's R&D spending is lower than some of its peers, reflecting its stage of development and focus on specific clinical programs.
• The shareholder lawsuits are a significant risk, similar to those faced by other companies in the industry that have experienced clinical trial setbacks or regulatory scrutiny.

Legal Proceedings

• A shareholder class action complaint, captioned Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, was filed in the U.S. District Court for the District of Nevada.
• A second, related putative securities class action was filed in the same court asserting similar claims against the same defendants, captioned Way v. BioVie Inc. et al., No. 2:24-cv-00361.
• The court consolidated these two actions under the caption In re BioVie Inc. Securities Litigation, No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel.
• The lead plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the Companys business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable AD, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder.
• The defendants filed a motion to dismiss the amended complaint on August 21, 2024, and that motion was fully briefed as of December 5, 2024.
• On March 27, 2025, the court denied the defendants motion to dismiss, allowing the case to move into fact discovery.
• A shareholder derivative lawsuit was filed in the United States District Court for the District of Nevada by putative stockholder Andrew Hulm, allegedly on behalf of the Company, that piggy-backs on the securities class action also pending in that court.
• A second shareholder derivative lawsuit was filed in the United States District Court for the District of Nevada by putative stockholder William Settel, allegedly on behalf of the Company, that alleges essentially the same claims as in the Hulm derivative litigation, against the same defendants based on the same alleged conduct.

Related Party Transactions

• During the nine months ended March 31, 2025, the Company paid a Director of the Company $50,000 for consulting services which are reflected as a component of selling, general and administrative expenses on the accompanying condensed statement of operations and comprehensive loss.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and the potential for a decrease in the stock price due to the company's financial challenges and legal proceedings.
• Employees face uncertainty due to the company's going concern warning and potential need for cost-cutting measures.
• Patients may benefit from the company's clinical development programs if the drug candidates are successful in treating neurodegenerative and liver diseases.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.
• Suppliers and vendors may be impacted by the company's financial challenges and potential need to reduce expenses.

Next Steps

• Finalizing the protocol design for the Phase 3 study of BIV201.
• Commencing the trial for the long COVID program in May 2025.
• Continuing the Phase 2 study of bezisterim (NE3107) for Parkinson's disease.
• Securing additional financing to fund operations.
• Defending against the shareholder class action and derivative lawsuits.

Key Dates

Keywords

BioVie, bezisterim, NE3107, BIV201, Alzheimer's disease, Parkinson's disease, long COVID, liver disease, clinical trials, financial results, pharmaceutical, biotechnology